LLC1 (Lewis Lung / LL/2) Syngeneic Model Service for Lung Cancer

The LLC1 (Lewis Lung / LL/2) syngeneic model is the most published transplantable tumor system in oncology research, engrafting a hypermutated, highly tumorigenic murine lung carcinoma into syngeneic C57BL/6 hosts to deliver robust primary tumors and authentic metastatic spread across four validated implantation routes. Alfa Cytology delivers this landmark model as a complete preclinical service — authenticated ATCC-line banking, subcutaneous, intravenous, intranasal, and intrathoracic implantation formats, quantitative bioluminescence tracking, chemotherapy and immunotherapy evaluation, and full histopathology — giving sponsors a seventy-five-year publication record behind every data package.

Overview of LLC1 (Lewis Lung / LL/2) Syngeneic Model for Lung Cancer

Few tumors in history carry the pedigree of the Lewis lung carcinoma: in 1951, Dr. Margaret R. Lewis of the Wistar Institute discovered a spontaneous epidermoid carcinoma in the lung of a C57BL mouse, and the tumor became one of the first transplantable cancer models ever maintained, passed from laboratory to laboratory by subcutaneous and intramuscular implantation for decades before Bertram and Janik finally adapted it to in vitro culture in 1980 — the LLC1 (LL/2) line, deposited as ATCC CRL-1642. By one reckoning the model has served more than 5,000 published studies since 1956, and it remains, by the consensus of the lung cancer modeling literature, essentially the only reproducible syngeneic model for non-small cell lung cancer. Modern whole-exome sequencing has illuminated why it behaves so distinctively: LLC1 is a hypermutated tumor carrying Kras G12C and Nras mutations together with Trp53 and Cdkn2a lesions, descended from a male C57BL/6L mouse — a transitional strain between C57BL/6J and C57BL/6N — with its extreme mutation burden attributed to decades of laboratory passaging and extensive regional mutation clusters across its genome. The cells are anaplastic, highly tumorigenic, poorly immunogenic, and richly vascularized, and they metastasize from flank tumors to lung, lymph nodes, liver, myocardium, and pancreas.

Fig 1. Bioluminescence imaging comparison in the LLC1 (Lewis lung) orthotopic model — LLC-GLF tail vein injection timeline, IVIS luminescence at day 21 showing lung tumor signals in unshaved albino, unshaved wild-type and shaved wild-type C57BL/6J mice, with radiance color scale (Min 1.00e4, Max 1.00e6 photons/sec/cm²/sr). (Yamada‐Hara, Miki, et al., 2024)

The model's versatility rests on four implantation geometries, each with a distinct scientific personality. The subcutaneous flank format — typically 10⁶ cells — is the classic primary-tumor efficacy platform, with caliper monitoring complemented by quantitative bioluminescence and ex vivo lung bioluminometry against standard curves. The tail-vein experimental metastasis format seeds the lung rapidly, though the literature candidly documents its drawbacks: thromboembolic sudden death, tumor development at multiple anatomical sites, and incomplete lung penetrance — limitations that motivated the intranasal instillation alternative, which trades the vascular route for simplicity and improved reproducibility while preserving the lung microenvironment for tumor-initiation studies. The intrathoracic orthotopic implantation format places tumor directly within the lung, and orthotopic lung tumors in this system release circulating tumor cells into the bloodstream — CTCs that can be captured, expanded, and shown to form metastases in liver, brain, adrenal glands, bone, and mediastinal lymph nodes with organ-specific tropism, offering a rare window on the full metastatic cascade in an immunocompetent host. Two engineered extensions deserve note: luciferase-tagged derivatives enable three-dimensional tumor imaging in white- and black-furred C57BL/6 mice alike, and the LLC-OVA line — stably expressing ovalbumin as a model antigen — enables antigen-specific T-cell tracking by tetramer staining and ELISpot for vaccine and adoptive-therapy development. With chemotherapy and targeted-therapy benchmarks spanning vinorelbine, carboplatin, sunitinib, and erlotinib, and single-cell cloning studies revealing striking in vitro-versus-in vivo growth divergence among subclones, the LLC1 system remains the indispensable lung cancer workhorse.

Cell Line Information: LLC1 (Lewis Lung / LL/2)

LLC1 — also catalogued as LL/2 or Lewis lung carcinoma line 1 (ATCC CRL-1642; Cellosaurus CVCL_8658; Cytion 305166; RIKEN RCB1491) — is the in vitro-culture derivative of the spontaneous 1951 Lewis lung carcinoma, distributed by the American Type Culture Collection and international repositories. Luciferase-tagged (LLC-Luc) and ovalbumin-expressing (LLC-OVA) derivatives extend the platform into optical imaging and antigen-specific immunology. Core characteristics are compiled below.

Our Services

Engaging Alfa Cytology for the LLC1 syngeneic model places a seventy-five-year publication legacy under one accountable team: authenticated ATCC-provenance banks are maintained at low passage, syngeneic C57BL/6 hosts are sourced and acclimated, tumors are established by whichever of the four validated geometries — subcutaneous, tail-vein, intranasal, or intrathoracic — best serves the scientific question, luciferase-tagged cohorts are tracked by scheduled imaging and quantitative lung bioluminometry, and treatment arms from chemotherapy benchmarks to immunotherapy combinations run through terminal multi-organ histopathology, all under IACUC-compliant conditions and returned as an audit-ready data package.

Workflow of LLC1 (Lewis Lung / LL/2) Syngeneic Model Construction

LLC1 studies are defined by route selection — each geometry answers a different scientific question — wrapped around the same disciplined cell preparation. A standard program proceeds as follows.

1. Cell preparation and quality control: LLC1 or LLC-Luc cells are expanded at low passage, confirmed mycoplasma-free, and luciferase activity validated in vitro; single-cell suspensions at defined concentrations are prepared fresh, with mixed adherent–suspension morphology respected during harvest.
2. Host selection and acclimation: Male or female C57BL/6 mice, typically 6–8 weeks of age, are quarantined and acclimated in a specific-pathogen-free barrier facility, with white- and black-furred cohorts both documented as compatible with quantitative bioluminescence imaging.
3. Implantation: subcutaneous route. 10⁶ cells in 0.1 mL sterile PBS are injected into the flank; the site is compressed briefly on needle withdrawal, and rapidly growing vascularized primary tumors become palpable within the first week.
4. Implantation: intravenous route. A defined cell dose (on the order of 2 × 10⁵–10⁶ cells in 0.2 mL PBS) is administered via the lateral tail vein, seeding pulmonary lesions; injection volume and speed are controlled to minimize thromboembolic risk.
5. Implantation: intranasal or intrathoracic routes. For microenvironment-focused studies, cells are instilled intranasally under brief anesthesia as a simple, reproducible alternative to tail-vein delivery; for true orthotopic modeling, a thoracotomy delivers cells or fragments directly into the lung parenchyma under sterile technique.
6. Randomization and treatment: Mice are randomized at a defined tumor volume, imaging threshold, or post-implantation interval, and test articles — chemotherapeutics, targeted agents, checkpoint inhibitors, or immunotherapy combinations — are dosed per protocol with body weight and clinical signs recorded.
7. Longitudinal monitoring: Flank tumors are measured by caliper; luciferase-tagged cohorts undergo whole-body bioluminescence imaging after intraperitoneal D-luciferin injection on the protocol cadence, with ex vivo organ imaging at interim or terminal time points to map metastatic distribution.
8. Endpoint analysis and reporting: At termination, primary tumors and lung, liver, lymph nodes, and other organs are resected and weighed; tissues undergo H&E with metastatic nodule enumeration, immunohistochemistry (CD8, FoxP3, F4/80, CD31, PD-L1 panels), quantitative lung bioluminometry against cell-count standard curves where specified, and CTC analysis for orthotopic-format studies, with all data consolidated into the final report.

Fig 2. LLC1 (Lewis Lung / LL/2)Syngeneic Model construction workflow.

Case Study-LLC1 (Lewis Lung / LL/2) Syngeneic Model Development

Alfa Cytology has applied the LLC1 syngeneic platform to preclinical programs spanning chemotherapy and targeted-therapy benchmarks, immunotherapy in poorly immunogenic tumors, metastasis and circulating-tumor-cell research, and vaccine-development studies in lung cancer. In these engagements, caliper and quantitative bioluminescence readouts tracked primary and metastatic tumor kinetics across implantation routes, while terminal multi-organ histopathology with immune-marker panels and ex vivo bioluminometric quantification completed the pharmacological assessment. Study parameters — implantation route, inoculum, monitoring cadence, and endpoint panels — are tailored to each program. Case materials can be shared under confidentiality agreements upon request.

Why Choose Alfa Cytology?

LLC1 is a model with seventy-five years of accumulated expectations: any weakness in cell stewardship, route selection, or metastasis quantification is instantly visible against its enormous publication record. Alfa Cytology fields the full capability set — authenticated banking, four implantation geometries, quantitative bioluminescence, and multi-organ pathology — making the LLC1 / LLC-Luc syngeneic model a dependable backbone for your lung cancer program.

• ATCC-documented provenance (CRL-1642), with low-passage banking and authenticated LLC-Luc and LLC-OVA derivatives.
• Four validated implantation geometries — subcutaneous, tail-vein, intranasal, and intrathoracic — matched to the scientific question.
• Honest route counseling, applying documented tail-vein limitations when intranasal or intrathoracic designs serve better.
• CTC expertise, including capture and metastatic-competence analysis from orthotopic lung tumors.
• Quantitative lung bioluminometry against cell-count standard curves for metastatic-load quantification.
• Antigen-specific formats, with LLC-OVA enabling tetramer and ELISpot T-cell tracking for vaccine programs.
• IACUC-compliant, documentation-rich operations delivering audit-ready records throughout the study.

Contact Us

If your lung cancer program needs the field's most published tumor model with the route expertise to exploit it fully, contact us today to discuss LLC1 / LLC-Luc study design, implantation geometry, and endpoint strategy with our scientific team. Reach out for a confidential consultation and project quotation — Alfa Cytology looks forward to advancing your next preclinical study.

For research use only. Not intended for any clinical use.